BioVie (BIVI) Set to Announce Earnings on Monday

BioVie (NASDAQ:BIVI) will announce its earnings results on Monday, April 22nd.

BioVie (NASDAQ:BIVI) last released its earnings results on Monday, February 12th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.10.

BioVie Stock Performance

NASDAQ BIVI opened at $0.49 on Friday. The stock has a market capitalization of $19.42 million, a price-to-earnings ratio of -0.42 and a beta of 0.79. The stock’s 50 day moving average price is $0.79 and its two-hundred day moving average price is $1.84. BioVie has a 52 week low of $0.45 and a 52 week high of $8.69.

Institutional Investors Weigh In On BioVie

Several large investors have recently made changes to their positions in the stock. UBS Group AG raised its stake in BioVie by 284.2% in the 4th quarter. UBS Group AG now owns 3,565 shares of the company’s stock valued at $28,000 after acquiring an additional 2,637 shares during the period. Commonwealth Equity Services LLC raised its stake in BioVie by 33.5% in the 1st quarter. Commonwealth Equity Services LLC now owns 16,255 shares of the company’s stock valued at $131,000 after acquiring an additional 4,080 shares during the period. Tower Research Capital LLC TRC raised its stake in BioVie by 2,706.5% in the 1st quarter. Tower Research Capital LLC TRC now owns 4,294 shares of the company’s stock valued at $35,000 after acquiring an additional 4,141 shares during the period. Wells Fargo & Company MN raised its stake in BioVie by 162.3% in the 4th quarter. Wells Fargo & Company MN now owns 7,044 shares of the company’s stock valued at $55,000 after acquiring an additional 4,359 shares during the period. Finally, Bank of America Corp DE raised its stake in BioVie by 33.3% in the 1st quarter. Bank of America Corp DE now owns 24,596 shares of the company’s stock valued at $199,000 after acquiring an additional 6,138 shares during the period. Institutional investors and hedge funds own 4.59% of the company’s stock.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.